Substituted Quinoline Derivatives for Tuberculosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis, particularly multi-drug resistant strains and latent infections, are lengthy, require multiple drugs, and face challenges with patient compliance and emerging antibiotic resistance, necessitating new compounds with novel mechanisms of action.
Innovation Solution
Development of novel substituted quinoline derivatives that inhibit bacterial growth, including Mycobacterium tuberculosis and other pathogenic bacteria, offering a potential shorter treatment duration and improved compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple drugs are combined for TB treatment, then effectiveness against bacterial strains is improved, but treatment duration and complexity increase
Solution Approach 1:
The patent combines multiple pharmacophores (fluoroquinolone, pyrazine carboxamide, and additional heterocyclic moieties) into a single molecular entity, creating a multi-functional compound that can simultaneously target multiple bacterial pathways, thereby potentially reducing treatment duration while maintaining effectiveness
Solution Approach 2:
The invention creates composite molecular structures by fusing different heterocyclic rings and functional groups into a single complex quinoline derivative, where each component contributes specific antibacterial properties, enabling multi-target activity in one molecule
2Reliability
If multiple drugs are administered, then bacterial coverage is improved, but patient compliance deteriorates
Solution Approach 1:
By consolidating multiple drug functions into a single compound, the invention simplifies the administration regimen from multiple separate medications to one unified drug, thereby improving patient compliance while maintaining broad bacterial coverage through the compound's multi-target mechanism
3Reliability
If treatment regimen is extended, then sterilizing effect is improved, but loss of time increases
Solution Approach 1:
The invention modifies the chemical parameters of existing anti-TB drugs by introducing additional heterocyclic substituents and functional groups, which enhances the compound's potency and sterilizing activity, potentially allowing for shorter treatment durations while achieving the same therapeutic effect
4Reliability
If new drug mechanisms are developed, then activity against resistant strains is improved, but device complexity increases
Solution Approach 1:
The patent employs composite molecular architecture by integrating multiple heterocyclic systems (fluoroquinolone, pyrazine carboxamide, and additional rings) into a single complex structure, where each component contributes to resistance-breaking activity through different mechanisms, thereby achieving enhanced efficacy against MDR-TB despite increased molecular complexity
Data Source
AI summary
The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or composit ions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.